Abstract
To the Editor: We read with interest the article regarding Australia's approach to managing the challenges of pharmaceutical opioid utilisation.1 The various regulatory, service delivery and educational activities described would appear to provide a comprehensive response to this problem. However, we were surprised to note the absence of any reference to the potential of pharmacogenomics in identifying patients at increased risk of opioid toxicity.
Original language | English |
---|---|
Pages (from-to) | 237-237.e1 |
Number of pages | 1 |
Journal | Medical Journal of Australia |
Volume | 211 |
Issue number | 5 |
DOIs | |
Publication status | Published - Sep 2019 |
Externally published | Yes |
Keywords
- Analgesics, opioid
- Codeine
- Pharmacogenomics